Regulation of cytokine signaling and inflammation

Cytokine and Growth Factor Reviews

Volumn 13, Issue 4-5, 2002, Pages 413-421

  Hanada, Toshitkatsu ^a   Yoshimura, Akihiko ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Cytokine signaling; Inflammation; Interleukin

Indexed keywords

CYTOKINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 18; INTERLEUKIN 4; JANUS KINASE; RAS PROTEIN; SMAD PROTEIN; STAT PROTEIN; STAT3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL MODEL; DISEASE MODEL; FIBROBLAST; INFLAMMATION; NEGATIVE FEEDBACK; PROTEIN DOMAIN; PROTEIN STRUCTURE; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; SYNOVIUM;

ANIMALS; CYTOKINES; DNA-BINDING PROTEINS; FEEDBACK, BIOCHEMICAL; GENE EXPRESSION REGULATION; GROWTH SUBSTANCES; HUMANS; I-KAPPA B PROTEINS; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; MICE; MICE, KNOCKOUT; MULTIGENE FAMILY; NF-KAPPA B; PHOSPHORYLATION; PROTEIN KINASES; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECEPTORS, CYTOKINE; REPRESSOR PROTEINS; SIGNAL TRANSDUCTION; SMAD PROTEINS; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

EID: 0036694663     PISSN: 13596101     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6101(02)00026-6     Document Type: Review

References (87)

1. Baldwin Jr, AS. The NF-κB and I kappaB proteins: 1996 new discoveries and insights. Ann. Rev. Immunol. 14:649-83.
2. Vincenti MP, Coon CI, Brinckerhoff CE. Nuclear factor kappaB/p50 activates an element in the distal matrix metalloproteinase 1 promoter in interleukin-I beta-stimulated synovial fibroblasts. Arthritis Rheum 1998;41:1987-94.
3. Baldwin Jr AS. The NF-κB and I kappaB proteins: new discoveries and insights. Ann Rev Immunol 1996;14:649-83.
4. Nomura Y. NF-κB activation and I kappaB alpha dynamism involved in iNOS and chemokine induction in astroglial cells. Life Sci 2001;68:1695-701.
5. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2001;2:675-80.
6. Zandi E, Chen Y, Karin M. Direct phosphorylation of I kappaB by IKKα and IKKβ: discrimination between free and NF-κB-bound substrate. Science 1998;281:1360-3.
7. Chen Z, Hagler J, Palombella VJ, et al. Signal-induced site-specific phosphorylation targets I kappaB alpha to the ubiquitin-proteasome pathway. Genes Dev 1995;9:1586-97.
8. Delhase M, Hayakawa M, Chen Y, Karin M. Positive and negative regulation of I kappaB kinase activity through IKKβ subunit phosphorylation. Science 1999;284:309-13.
9. Han ZN, Boyle DL, Manning AM, Firestein GS. AP-1 and NF-κB regulation in rheumatoid arthritis and murine collagen-induced arthritis. Autoimmunity 1998;28:197-208.
10. Miyazawa K, Mori A, Yamamoto K, Okudaira H. Constitutive transcription of the human interleukin-6 gene by rheumatoid synoviocytes: spontaneous activation of NF-κB and CBF1. Am J Pathol 1998;152:793-803.
11. Rahman A, Anwar KN, True AL, Malik AB. Thrombin-induced p65 homodimer binding to downstream NF-κB site of the promoter mediates endothelial ICAM-1 expression and neutrophil adhesion. J Immunol 1999;162:5466-76 [abstract/full text].
12. Schottelius AJ, Mayo MW, Sartor RB, Baldwin Jr AS. Interleukin-10 signaling blocks inhibitor of kappaB kinase activity and nuclear factor kappaB DNA binding. J Biol Chem 1999;274:31868-74.
13. Aronica MA, Mora AL, Mitchell DB, et al. Preferential role for NF-κB/Rel signaling in the type 1 but not type 2 T cell-dependent immune response in vivo. J Immunol 1999;163:5116-24.
14. Chen CC, Rosenbloom CL, Anderson DC, Manning AM. Selective inhibition of E-selectin, vascular cell adhesion molecule-1, and intercellular adhesion molecule-1 expression by inhibitors of I kappaB-alpha phosphorylation. J Immunol 1995;155:3538-45.
15. Uesugi T, Froh M, Arteel GE, Bradford BU, Gabele E, Wheeler MD, et al. Delivery of I kappaB super-repressor gene with adenovirus reduces early alcohol-induced liver injury in rats. Hepatology 2001;34:1149-57.
16. Oitzinger W, Hofer-Warbinek R, Schmid JA, Koshelnick Y, Binder BR, de Martin R. Adenovirus-mediated expression of a mutant I kappaB kinase 2 inhibits the response of endothelial cells to inflammatory stimuli. Blood 2001;97:1611-7.
17. Tak PP, Gerlag DM, Aupperle KR, et al. Inhibitor of nuclear factor kappaB kinase beta is a key regulator of synovial inflammation. Arthritis Rheum 2001;44:1897-907.
18. Lawrence T, Gilroy DW, Colville-Nash PR, Willoughby DA. Possible new role for NF-κB in the resolution of inflammation. Nat Med 2001;7:1291-7.
19. Hugot J-P, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001;411:599-603.
20. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001;411:603-6.
21. Thompson JE, Phillips RJ, Erdjument-Bromage H, Tempst P, Ghosh S. I kappaB-beta regulates the persistent response in a biphasic activation of NF-κB. Cell 1995;80:573-82.
22. Cooper JT, Stroka DM, Brostjan C, Palmetshofer A, Bach FH, Ferran C. A20 blocks endothelial cell activation through a NF-κB-dependent mechanism. J Biol Chem 1996;271:18068-73.
23. Opipari Jr AW, Hu HM, Yabkowitz R, Dixit VM. The A20 zinc finger protein protects cells from tumor necrosis factor cytotoxicity. J Biol Chem 1992;267:12424-7.
24. Song HY, Rothe M, Goeddel DV. The tumor necrosis factor-inducible zinc finger protein A20 interacts with TRAF1/TRAF2 and inhibits NF-κB activation. Proc Natl Acad Sci USA 1992;93:6721-5.
25. Heyninck K, De Valck D, Vanden Berghe W, et al. The zinc finger protein A20 inhibits TNF-induced NF-κB-dependent gene expression by interfering with an RIP- or TRAF2-mediated transactivation signal and directly binds to a novel NF-κB-inhibiting protein ABIN. J Cell Biol 1999;145:1471-82.
26. Lee EG, Boone DL, Chai S, et al. Failure to regulate TNF-induced NF-κB and cell death responses in A20-deficient mice. Science 2000;289:2350-4.
27. Letterio JJ, Roberts AB. Regulation of immune responses by TGFβ. Ann Rev Immunol 1998;16:137-61.
28. Babyatsky MW, Rossiter G, Podolsky DK. Expression of transforming growth factor and β in colonic mucosa in inflammatory bowel disease. Gastroenterology 1996;110:975-84.
29. Massague J, Wotton D. Transcriptional control by the TGFβ/Smad signaling system. EMBO J 2000;19:1745-54.
30. Massague J. TGFβ signal transduction. Ann Rev Biochem 1998;67:753-91.
31. Nakao A, Afrakhte M, Moren A, et al. Identification of Smad7, a TGFβ-inducible antagonist of TGFβ signalling. Nature 1997;389:631-5.
32. Imamura T, Takase M, Nishihara A, et al. Smad6 inhibits signalling by the TGFβ superfamily. Nature 1997;389:622-26.
33. Shull MM, Ormsby I, Kier AB, et al. Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease. Nature 1992;359:693-9.
34. Gorelik L, Flavell RA. Abrogation of TGFβ signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity 2000;12:171-81.
35. Yang X, Letterio JJ, Lechleider RJ. Targeted disruption of Smad3 results in impaired mucosal immunity and diminished T cell responsiveness to TGFβ. EMBO J 1999;18:1280-91
36. Nakao A, Miike S, Hatano M. Blockade of transforming growth factor β/Smad signaling in T cells by overexpression of Smad7 enhances antigen-induced airway inflammation and airway reactivity. J Exp Med 2000;192:151-8.
37. Monteleone G, Kumberova A, Croft NM, McKenzie C, Steer HW, MacDonald TT. Blocking Smad7 restores TGFβ1 signaling in chronic inflammatory bowel disease. J Clin Invest 2001;108:601-9.
38. Ihle JN. Cytokine receptor signalling. Nature 1995;377:591-4.
39. Ihle JN. STATs: signal transducers and activators of transcription. Cell 1996;84:331-4.
40. Darnell Jr JE. STATs and gene regulation. Science 1997;277:1630-5.
41. O'Farrell AM, Liu Y, Moore KW, Mui AL. IL-10 inhibits macrophage activation and proliferation by distinct signaling mechanisms: evidence for STAT3-dependent and -independent pathways. EMBO J 1998;17:1006-18.
42. Kaplan MH, Sun YL, Hoey T, Grusby MJ. Impaired IL-12 responses and enhanced development of Th2 cells in STAT4-deficient mice. Nature 1996;382:174-7.
43. Shimoda K, van Deursen J, Sangster MY. Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted STAT6 gene. Nature 1996;380:630-3.
44. Takeda K, Tanaka T, Shi W. Essential role of STAT6 in IL-4 signalling. Nature 1996;380:627-30.
45. Hirano T, Akira S, Taga T, Kishimoto T. Biological and clinical aspects of interleukin-6. Immunol Today 1990;11:443-9.
46. Sampath D, Castro M, Look DC, Holtzman MJ. Constitutive activation of an epithelial signal transducer and activator of transcription (STAT) pathway in asthma. J Clin Invest 1999;103:1353-61.
47. Wirtz S, Finotto S, Kanzler S, et al. Cutting edge: chronic intestinal inflammation in STAT-4 transgenic mice: characterization of disease and adoptive transfer by TNF- plus IFNγ-producing CD4+ T cells that respond to bacterial antigens. J Immunol 1999;162:1884-8.
48. Parrello T, Monteleone G, Cucchiara S, et al. Up-regulation of the IL-12 receptor beta 2 chain in Crohn's disease. J Immunol 2000;165:7234-9.
49. Takeda K, Kaisho T, Yoshida N, Takeda J, Kishimoto T, Akira S. STAT3 activation is responsible for IL-6-dependent T cell proliferation through preventing apoptosis: generation and characterization of T cell-specific STAT3-deficient mice. J Immunol 1998;161:4652-60.
50. Yamamoto M, Yoshizaki K, Kishimoto T, Ito H. Related articles IL-6 is required for the development of Th1 cell-mediated murine colitis. J Immunol 2000;164:4878-82.
51. Atreya R, Mudter J, Finotto S. Blockade of interleukin-6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo. Nat Med 2000;6:583-8.
52. Shirogane T, Fukada T, Muller JM, Shima DT, Hibi M, Hirano T. Synergistic roles for pim-1 and c-myc in STAT3-mediated cell cycle progression and antiapoptosis. Immunity 1999;11:709-19.
53. Takeda K, Clausen BE, Kaisho T, et al. Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of STAT3 in macrophages and neutrophils. Immunity 1999;10:39-49.
54. Yasukawa H, Sasaki A, Yoshimura A. Negative regulation of cytokine signaling pathways. Ann rev Immunol 2000;18:143-64.
55. Krebs DL, Hilton DJ. SOCS proteins: negative regulators of cytokine signaling. Stem Cells 2001;19:378-87.
56. Yoshimura A, Ohkubo T, Kiguchi T, et al. A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors. EMBO J 1995;14:2816-26.
57. Matsumoto A, Seki Y, Kubo M, et al. Suppression of STAT5 functions in liver mammary glands and T cells in cytokine-inducible SH2-containing protein 1 transgenic mice. Mol Cell Biol 1999;19:6396-407.
58. Endo TA, Masuhara M, Yokouchi M, et al. A new protein containing an SH2 domain that inhibits JAK kinases. Nature 1997;387:921-4.
59. Naka T, Narazaki M, Hirata T, et al. Structure and function of a new STAT-induced STAT inhibitor. Nature 1997;387:924-9.
60. Starr R, Willson TA, Viney EM, et al. A family of cytokine-inducible inhibitors of signalling. Nature 1997;387:917-21.
61. Masuhara M, Sakamoto H, Matsumoto A, et al. Cloning and characterization of Novel CIS family genes. Biochem Biophys Res Commun 1997;239:439-46.
62. Hilton DJ, Richardson RT, Alexander WS, Viney EM, Willson TA, Sprigg NS, et al. Twenty proteins containing a C-terminal SOCS box form five structural classes. Proc Natl Acad Sci USA 1998;95:114-9.
63. Yasukawa H, Misawa H, Sakamoto H. The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop. EMBO J 1999;18:1309-20.
64. Sasaki A, Yasukawa H, Suzuki A, et al. Cytokine-inducible SH2 protein-3 (CIS3/SOCS3) inhibits Janus tyrosine kinase by binding through the N-terminal kinase inhibitory region as well as SH2 domain. Genes Cells 1999;4:339-51.
65. Schmitz J, Weissenbach M, Haan S, Heinrich PC, Schaper F. SOCS3 exerts its inhibitory function on interleukin-6 signal transduction through the SHP-2 recruitment site of gp130. J Biol Chem 2000;275:12848-56.
66. Nicholson SE, De Souza D, Fabri LJ, et al. Suppressor of cytokine signaling-3 preferentially binds to the SHP-2-binding site on the shared cytokine receptor subunit gp130. Proc Natl Acad Sci USA 2000;97:6493-8.
67. Sasaki A, Yasukawa H, Shouda T, Kitamura T, Dikic I, Yoshimura A. CIS3/SOCS3 suppresses erythropoietin signaling by binding the EPO receptor and JAK2. J Biol Chem 2000;275:29338-47.
68. Naka T, Matsumoto T, Narazaki M, et al. Accelerated apoptosis of lymphocytes by augmented induction of Bax in SSI-1 (STAT-induced STAT inhibitor-1) deficient mice. Proc Natl Acad Sci USA 1998;95:15577-82.
69. Starr R, Metcalf D, Elefanty AG, et al. Liver degeneration and lymphoid deficiencies in mice lacking suppressor of cytokine signaling-1. Proc Natl Acad Sci USA 1998;95:14395-9.
70. Alexander WS, Starr R, Fenner JE, et al. SOCS1 Is a critical inhibitor of interferon gamma signaling and prevents the potentially fatal neonatal actions of this cytokine. Cell 1999;98:597-608.
71. Marine JC, McKay C, Topham DJ, et al. SOCS1 deficiency causes a lymphocyte-dependent perinatal lethality. Cell 1999;98:609-16.
72. Metcalf D, Mifsud S, Di Rago L, Nicola NA, Hilton DJ, Alexander WS. Polycystic kidneys and chronic inflammatory lesions are the delayed consequences of loss of the suppressor of cytokine signaling-1 (SOCS1). Proc Natl Acad Sci USA 2002;99:943-8.
73. Metcalf D, Di Rago L, Mifsud S, Hartley L, Alexander WS. The development of fatal myocarditis and polymyositis in mice heterozygous for IFNγ and lacking the SOCS1 gene. Proc Natl Acad Sci USA 2000;97:9174-9.
74. Naka T, Tsutsui H, Fujimoto M, et al. SOCS1/SSI-1-deficient NKT cells participate in severe hepatitis through dysregulated cross-talk inhibition of IFNγ and IL-4 signaling in vivo. Immunity 2001;14:535-45.
75. Ernst M, Inglese M, Waring P, et al. Defective gp130-mediated signal transducer and activator of transcription (STAT) signaling results in degenerative joint disease, gastrointestinal ulceration, and failure of uterine implantation. J Exp Med 2001;194:189-203.
76. Marine JC, McKay CD, Wang DJ, et al. SOCS3 is essential in the regulation of fetal liver erythropoiesis. Cell 1999;98:617-27.
77. Roberts AW, Robb L, Rakar S, et al. Placental defects and embryonic lethality in mice lacking suppressor of cytokine signaling 3. Proc Natl Acad Sci USA 2001;98:9324-9.
78. Cassatella MA, Gasperini S, Bovolenta C, et al. Interleukin-10 (IL-10) selectively enhances CIS3/SOCS3 mRNA expression in human neutrophils: evidence for an IL-10-induced pathway that is independent of STAT protein activation. Blood 1999;94:2880-9.
79. Boisclair YR, Wang J, Shi J, Hurst KR, Ooi GT. Role of the suppressor of cytokine signaling-3 in mediating the inhibitory effects of interleukin-1beta on the growth hormone-dependent transcription of the acid-labile subunit gene in liver cells. J Biol Chem 2000;275:3841-7.
80. Bode JG, Nimmesgern A, Schmitz J, et al. LPS and TNFalpha induce SOCS3 mRNA and inhibit IL-6-induced activation of STAT3 in macrophages. FEBS Lett 1999;463:365-70.
81. Suzuki A, Hanada T, Mitsuyama K, et al. CIS3/SOCS3/SSI3 plays a negative regulatory role in STAT3 activation and intestional inflammation. J Exp Med 2001;193:471-81.
82. Shouda T, Yoshida T, Hanada T. Induction of the cytokine signal regulator SOCS3/CIS3 as a therapeutic strategy for treating inflammatory arthritis. J Clin Invest 2001;108:1781-8.
83. Zhang JG, Farley A, Nicholson SE, et al. The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation. Proc Natl Acad Sci USA 1999;96:2071-6.
84. Elliott MJ, Maini RN, Feldmann M. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-10.
85. Elliott MJ, Maini RN, Feldmann M, et al. Repeated therapy with monoclonal antibody to tumor necrosis factor alpha (cA2) in patients with rheumatoid arthritis, Lancet 1994;344:1125-7.
86. Wendling D, Racadot E, Wijdenes J. Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. J Rheumatol 1993;20:259-62.
87. Yoshizaki K, Nishimoto N, Mihara M, Kishimoto T. Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody. Springer Serum Immunopathol 1998;20:247-59.